Dr. Tom Okarma, president and CEO of Geron
The Top 30 Innovations of the Last 30 Years
This was the title of a special episode of PBS’s award-winning Nightly Business Report that aired tonight. To provide viewers with perspective on innovation in healthcare, Anchor Susie Gharib conducted a one-on-one interview with Geron’s president and CEO, Dr. Tom Okarma. In the taped interview, which Russo Partners coordinated last week at the Waldorf-Astoria in New York City, Dr. Okarma discussed Geron’s position at the “dawn of a new era” in medicine with the company’s work in developing human embryonic stem cell-based therapies. Dr. Okarma’s comments properly position Geron’s significant progress in the transformation of medicine from scalpels and pills to one in which doctors will be able to administer therapies that create new tissue and “replacement parts.” The interview segment was a nice way to cap off Russo Partners’ recent work with Geron in announcing the FDA’s clearance of the company’s IND for OPC1, a stem cell therapy for spinal cord injury. Moreover, the segment was a nice lead-in to Tuesday’s Stem Cell Summit in New York City. The conference will feature product development updates from more than 30 top executives with stem cell companies along with the latest market forecast from analyst Robin Young. Russo Partners will continue with its streak of handling PR for major milestone events in the healthcare industry. Our team members will coordinate a major TV network’s live broadcasts from the Stem Cell Summit as well as line up interviews for more than 20 journalists with presenters.
